Journal article
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
- Abstract:
-
Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examin...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, 911.1KB, Terms of use)
-
- Publisher copy:
- 10.1177/1352458520943791
Authors
Bibliographic Details
- Publisher:
- SAGE Publications
- Journal:
- Multiple Sclerosis Journal More from this journal
- Volume:
- 26
- Issue:
- 10
- Pages:
- 1261-1264
- Place of publication:
- England
- Publication date:
- 2020-08-07
- Acceptance date:
- 2020-06-22
- DOI:
- EISSN:
-
1477-0970
- ISSN:
-
1352-4585
- Pmid:
-
32762494
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1124303
- Local pid:
-
pubs:1124303
- Deposit date:
-
2020-11-16
Terms of use
- Copyright holder:
- Wurm et al.
- Copyright date:
- 2020
- Rights statement:
- Copyright © 2020 The Author(s). This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
- Licence:
- CC Attribution-NonCommercial (CC BY-NC)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record